Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of 12 Ordinary Shares by Mrs. K. Thomson, a connected person to Director Mr. P. C. Thomson. This acquisition occurred on January 3, 2013, at a price of 1360.95 pence per share, resulting from the reinvestment of dividends under the GlaxoSmithKline ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the share price of 1360.95 pence per Ordinary Share on January 3, 2013.
- Confirm the total number of shares held by Mrs. K. Thomson following the acquisition of 12 shares.
- Review the terms of the GlaxoSmithKline ShareReward Plan regarding dividend reinvestment.